Female Sexual Dysfunction Treatment Market Size is Estimated to grow at a CAGR of 11.3% during the forecast period
The female sexual dysfunction treatment market was
estimated to have a global market value of USD 435.2 million in 2022, and over
the course of the forecast period, a CAGR of 11.3% is anticipated. A
psychiatric condition known as sexual dysfunction causes a woman to be unable
to enjoy intimate physical relationships. The market is expanding due to the
rising incidence of chronic illnesses.
Future market growth is significantly impacted by this
issue. Thanks to technological improvements, the sector is expected to have
robust growth during the predicted period. The market is expanding dramatically
due to the rising number of individuals with diabetes and cardiovascular
disease.
Request
For Free Sample Pages @ https://www.xresearch.biz/request-sample-pages/female-sexual-dysfunction-treatment-market
Growth Drivers
The market is growing due to rising patient numbers with
chronic diseases, advances in medical technology, and growing awareness of
sexual health issues. The industry is growing at a substantial rate thanks to
initiatives to de-stigmatize getting treatment. The true reason for the
increase in market revenue is the development of healthcare services and
infrastructure. The industry is expanding as a result of increasing awareness
campaigns and educational initiatives.
the creation of cutting-edge therapeutic modalities, novel
medications, and medical equipment with the specific goal of treating female
sexual dysfunction more successfully. As attitudes and practices around female
sexuality and healthcare change, there is a greater acceptability of talking
about and getting treatment for sexual dysfunction, which lowers stigma and
encourages women to get help.
Innovation and market expansion are driven by the
increasing investments made by pharmaceutical companies, research institutes,
and healthcare organizations in the study of female sexual health and
the development of innovative treatment modalities. Increasing access to
healthcare services and making it easier to diagnose and treat female sexual
dysfunction are two benefits of expanding the healthcare infrastructure,
particularly in developing nations. The industry is expanding as a result of an
increase in the prevalence of gynecological disorders.
Segmentation
By Route of
Administration
· Oral
· Parenteral
· Topical
By Distribution
Channel
· Hospital
Pharmacies
· Drug
Pharmacies
· Retail
Pharmacies
· Online
Stores
Based on Disease
· Hypoactive
sexual desire disorder
· Dyspareunia
· Others
By Drug Analysis
· Flibanserin
· Bremelanotide
· Ospemifane
· Estrogen
Therapy
· Others
Regional Outlook
· Asia
Pacific
· North
America
· Latin
America
· Europe
· Middle
East and Africa
Key Players
· Pfizer
Inc
· Amag
Pharmaceuticals
· BioSante
Pharmaceuticals
· Shionogi
and Co.
· Patatin
Technologies and Inc
· Teva
Pharmaceuticals Industries Ltd.
· Apricus
Biosciences Inc
· Novartis
· Johnson
and Johnson
· Other
Players
For
More Information about this Report @ https://www.xresearch.biz/shop/female-sexual-dysfunction-treatment-market
About
Us: -
xResearch is a
market research and consulting organization that uses unique data, expert
analysis, and new technologies to create trusted intelligence on industries.
Our research is focused on delivering an informed and impartial view on
essential market data of industry, and it is primarily driven by an in-depth
study covering the following parameters: Market Sizing and Forecasting, Market
Segmentation, Competitive Analysis, Strategic Assessment and Business
Modelling.
Contact:
Company Name: xResearch
Contact Person: James Lin
Email: sales@xresearch.biz
Phone: +1 718-619-8140
Comments
Post a Comment